Shares of Solara Active Pharma Sciences Ltd plunged 8.77% to Rs 563.00 in early trade on Thursday after the company reported a sharp deterioration in its financial performance for the quarter ended September 2025 (Q2 FY26).
Earnings snapshot
The company reported a net loss of Rs 10.10 crore in Q2 FY26, compared with a net profit of Rs 8.01 crore in the corresponding quarter last year.
Revenue from operations declined 9.63% year-on-year to Rs 313.54 crore, from Rs 346.95 crore in Q2 FY25.
Operating profit margin (OPM) fell sharply to 11.08% from 17.67% in the previous year, while profit before depreciation and tax (PBDT) dropped 57% to Rs 14.39 crore from Rs 33.35 crore.
The company reported a loss before tax (PBT) of Rs 10.10 crore, reversing a profit of Rs 8.01 crore last year.
Stock performance
As of 9:52 AM on November 6, Solara Active Pharma was trading at Rs 563, down Rs 54.15 from its previous close of Rs 617.15. The stock moved within a day range of Rs 502.30 to Rs 575.00, with a market capitalization of Rs 2,505 crore.
The company currently has a P/E ratio of 97.33, highlighting its elevated valuation despite the loss reported in Q2.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
